NCT03556982

CD123-Targeted CAR-T in Treating Patients With Relapsed/Refractory Acute Myelocytic Leukemia(AML)

Study Summary

The purpose of this study is to evaluate the safety and efficiency of CD123-Targeted CAR-T in Treating Patients with relapsed/refractory AML

Want to learn more about this trial?

Request More Info

Interventions

CART-123 cellsBIOLOGICAL
CD123-Targeted CAR-T cells are infused to patient received FC chemotherapy

Study Locations

FacilityCityStateCountry
307 Hospital of PLABeijingBeijing 100071China

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026